Patients with chronic obstructive pulmonary disease (COPD) face a significant cardiovascular burden both before and after diagnosis. Analyses presented at the European Respiratory Society (ERS) ...

Telemedicine significantly improved quality of life and inhaler technique in advanced COPD patients compared to traditional ...

The biologic dosed every 2 weeks reduced moderate or severe COPD exacerbations over 52 weeks by a relative 15.4% compared ...

Biological therapy was associated with significant changes in lung structure and, by extension, improved lung function in ...

A phase 3 trial evaluating benralizumab for the treatment of COPD did not meet its primary endpoint, according to AstraZeneca.

A new study published in The American Journal of Medicine found tirzepatide, which is prescribed for diabetes and weight ...

While treatment with benralizumab showed numerical improvement over placebo for the primary endpoint, the result was not statistically significant. A phase 3 trial evaluating benralizumab for the ...

Samay founder and CEO Dr. Maria Artunduaga says things changed pretty quickly for her startup after winning the MedTech ...

Treatment improved patient reported outcomes, reduced viral load, and maintained lung function compared to placebo; Multi-center, international trial ...

Previous non-experimental studies suggest an association between paracetamol exposure in the first year of life and subsequent asthma and eczema developing in childhood; however, randomised trials are ...

C hronic Obstructive Pulmonary Disease (COPD) is a progressive lung condition—primarily chronic bronchitis and emphysema—characterised by persistent respiratory symptoms and airflow limitation.